<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049620</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-0905</org_study_id>
    <nct_id>NCT01049620</nct_id>
  </id_info>
  <brief_title>RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer</brief_title>
  <official_title>A Phase I Dose Finding Study of RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is expected that RAD001 works in gastric cancer by inhibiting PI3K/AKT/mTOR pathway and
      Hif1A (hypoxia inducible factor 1, alpha subunit), a key player in angiogenesis and the
      growth of tumors like renal cell carcinoma.However, RAD001 alone looks not enough to control
      gastric cancer. By the mechanisms above, RAD001 can show additive or synergistic effect in
      combination with conventional chemotherapy. In this study, XELOX was selected as a
      conventional combination chemotherapy because it was proven very active and safe in gastric
      cancer. Combination of XELOX and RAD001 has been never tried for the treatment of cancer
      patients yet. So, the optimal dose will be first determined in this phase I study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the first cohort of this phase I study, each drug of capecitabine, oxaliplatin, and
      RAD001 will be started at one or two dose below the ordinary full dose of each drug as a
      single agent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the maximum tolerated dose (MTD)</measure>
    <time_frame>1year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker study</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Xelox+RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001, Capecitabine, Oxaliplatin</intervention_name>
    <description>Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21
Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21
Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21
Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21</description>
    <arm_group_label>Xelox+RAD001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented unresectable or metastatic adenocarcinoma
             of stomach or gastroesophageal junction

          -  No history of chemotherapy or radiation

          -  Age 18 to 70 years old

          -  Estimated life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate bone marrow function (white blood cell counts &gt;3,000/uL, absolute neutrophil
             count&gt;1,500/uL, Platelets&gt;100,000/uL, Hgb&gt;8 g/dL)

          -  Adequate kidney function (creatinine&lt;1.5 mg/dL)

          -  Adequate liver function (bilirubin&lt;1.5 mg/dL, aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) level &lt;3 times the upper normal limit (5 times for
             patients with liver metastasis))

          -  Signed written informed consent

        Exclusion Criteria:

          -  Past or concurrent history of neoplasm other than gastric adenocarcinoma except for
             curatively treated basal cell carcinoma of skin or in situ carcinoma of the cervix
             uteri

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start

          -  Presence of central nervous system metastasis

          -  Bowel obstruction

          -  Evidence of serious gastrointestinal bleeding

          -  Peripheral neuropathy (NCI CTC AE version 3.0 &gt; Grade I)

          -  History of significant neurologic or psychiatric disorders

          -  Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          -  Other serious illness or medical conditions

          -  Patients with known history of ischemic heart disease and/or with myocardial
             infarction

          -  Known allergy to study drugs

          -  Administration of drugs showing interaction with RAD001
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>January 11, 2015</last_update_submitted>
  <last_update_submitted_qc>January 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>XELOX</keyword>
  <keyword>RAD001</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

